3 stories found
Novartis saw its stock price fall sharply after announcing that a late-stage clinical trial for its del-desiran drug failed to meet its primary efficacy goal. The setback marks the third recent disappointment for the pharmaceutical company’s development pipeline.
The company released progress details on the HARBOR study evaluating delpacibart etedesiran, a novel therapy aimed at treating myotonic dystrophy type 1.
Following the death of country music icon Dolly Parton, public figures such as Jessica Simpson have paid tribute to her unparalleled influence and irreplaceable status in entertainment. Media outlets are also marking the occasion with retrospective features and fan engagement quizzes celebrating her career.